Study Evaluating the Safety of MOA-728 Administered Orally to Healthy Subjects

Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of MOA-728 Administered Orally to Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00311350

Enrollment

Registered

2006-04-05

Start date

2006-03-31

Completion date

2006-08-31

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation, Postoperative Complications

Keywords

Safety, Health, Pharmacokinetics, ileus

Brief summary

This is the first multiple-dose experience in humans with MOA-728 in an oral formulation. This study will provide an assessment of the safety, tolerability, and pharmacokinetics (PK) of MOA-728 following administration of ascending multiple oral doses to healthy subjects.

Interventions

DRUGMOA-728

Study design

Allocation

RANDOMIZED

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy men and women

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026